COVID-19 Continues to Change the Retail Real Estate Landscape 

 

On this episode of Dirt Work, we were joined by Austin Clinkscales, Principal at Ladera Properties, a real estate developer, investment firm and operator focused on the retail sector in Texas and Oklahoma, to discuss how COVID-19 has impacted that already ever-changing retail real estate market. Retail is a tough business because of inherent limitations to control consumer behavior and has been impacted by many market shifts in the last several decades including the dot-com boom, the 08/09 recession and the emergence of retail alternatives such as e-commerce.

Clinkscales believes that the silver lining of the coronavirus disruption is opportunities created by reduced competition going after new development opportunities as others in the market are working to control pandemic-related damage to their existing portfolios.

COVID-19 has continued to change the retail landscape across malls, power-centers (e.g. shopping centers anchored by a Walmart, Target, etc.), neighborhood retail and restaurants. While the nuances impacting each vertical differ Clinkscales believes that liquidity, technology, health, and general ability to increase consumer confidence will separate the winners and losers following the pandemic. For listeners interested in learning more about changes in the retail section, Austin recommends CBRE’s Global Retail Research channel.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More